Celsion (NASDAQ:CLSN) Shares Up 10.4%

Celsion Co. (NASDAQ:CLSN)’s share price shot up 10.4% during mid-day trading on Tuesday . The stock traded as high as $1.66 and last traded at $1.59, 296,283 shares traded hands during mid-day trading. An increase of 128% from the average session volume of 130,090 shares. The stock had previously closed at $1.44.

Separately, Zacks Investment Research downgraded shares of Celsion from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd.

The firm’s 50 day moving average price is $1.47 and its 200-day moving average price is $1.70. The firm has a market cap of $35.66 million, a price-to-earnings ratio of -2.35 and a beta of 1.86. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.58 and a quick ratio of 2.58.

Celsion (NASDAQ:CLSN) last announced its quarterly earnings data on Friday, November 15th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.05. The business had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative net margin of 1,653.20% and a negative return on equity of 57.46%. Analysts expect that Celsion Co. will post -1.09 EPS for the current year.

An institutional investor recently raised its position in Celsion stock. Vanguard Group Inc. lifted its stake in Celsion Co. (NASDAQ:CLSN) by 43.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 704,651 shares of the biotechnology company’s stock after acquiring an additional 211,779 shares during the period. Vanguard Group Inc. owned approximately 3.44% of Celsion worth $1,282,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 5.76% of the company’s stock.

Celsion Company Profile (NASDAQ:CLSN)

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.

Further Reading: What is a stock portfolio tracker?

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.